Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating HER3 mutations in breast cancer

11 Jun 2018

Abstract excerpt

// Rosalin Mishra 1 , Samar Alanazi 1 , Long Yuan 1 , Thomas Solomon 1 , Tarjani M. Thaker 2 , Natalia Jura 2 and Joan T. Garrett 1 1 James L. Winkle College of Pharmacy, University of Ohio, Cincinnati, Ohio, USA 2 Department of Cellular and Molecular Pharmacology, Cardiovascular Research Institute, University of California, San Francisco, California, USA Correspondence to: Joan T. Garrett, email:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29963236
DOI: 10.18632/oncotarget.25576

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating HER3 mutations in breast cancerPMID 29963236Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

Genomic alterations of ERBB receptors in cancer: clinical implicationsSemantic proximity Read ↗

HER family in cancer progression: From discovery to 2020 and beyond.Semantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

A review of HER2 overexpression and somatic mutations in cancers.Semantic proximity Read ↗

Activating HER2 mutations as emerging targets in multiple solid cancersSemantic proximity Read ↗

Targeting HER proteins in cancer therapy and the role of the non-target HER3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.